Alnylam Pharmaceuticals (ALNY) valuation
Alnylam Pharmaceuticals P/E ratio history
Alnylam Pharmaceuticals trades at 41.5 times its earnings over the last twelve months and 14.9 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $397.65 | $2.33 | 170.7 |
| Dec 31, 2024 | $235.31 | -$2.18 | n/m |
| Dec 31, 2023 | $191.41 | -$3.52 | n/m |
| Dec 31, 2022 | $237.65 | -$9.30 | n/m |
| Dec 31, 2021 | $169.58 | -$7.20 | n/m |
| Dec 31, 2020 | $129.97 | -$7.45 | n/m |
| Dec 31, 2019 | $115.17 | -$8.15 | n/m |
| Dec 31, 2018 | $72.91 | -$7.56 | n/m |
| Dec 31, 2017 | $127.05 | -$5.42 | n/m |
| Dec 31, 2016 | $37.44 | -$4.78 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Alnylam Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Alnylam PharmaceuticalsALNY | $22.1B | 41.5 | 14.9 | 4.4 |
| BioNTechBNTX | $22.3B | — | — | 7.2 |
| IncyteINCY | $24.4B | 64.0 | 16.2 | 4.1 |
| InsmedINSM | $24.6B | — | — | 16.2 |
| CibusCBRS | $24.7B | — | — | — |
| ExelixisEXEL | $17.2B | 20.7 | 16.8 | 6.9 |
| BiogenBIIB | $37.5B | 109.3 | 16.6 | 3.6 |
| ModernaMRNA | $88.0B | — | — | 39.5 |
| RegeneronREGN | $97.3B | 23.0 | 17.2 | 6.3 |
| Peer median | 43.5 | 16.7 | 6.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ALNY financials · ALNY returns
No forecast, no recommendation. This page describes Alnylam Pharmaceuticals from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.